Table 2.
Incidence Rate of Outcomes in New MRA Users Compared With Nonusers
| Outcome | Overall (N=5650) | MRA Use | |
|---|---|---|---|
| Never Used (n=5390) | New Use (n=260) | ||
| AF progression, No. (%) (N=5620)a | 1241 (22.08) | 1186 (22.13) | 55 (21.15) |
| All‐cause death | 372 (3.39) | 351 (3.32) | 21 (5.39) |
| Cardiovascular death | 134 (1.22) | 126 (1.19) | 8 (2.06) |
| First stroke, non‐CNS embolism, or TIA | 142 (1.31) | 141 (1.35) | 1 (0.26) |
| New‐onset HF (N=4174)b | 79 (0.98) | 75 (0.95) | 4 (2.34) |
| First cardiovascular hospitalization | 1376 (14.54) | 1306 (14.28) | 70 (22.08) |
Event rates per 100 patient‐years of follow‐up. CNS indicates central nervous system; TIA, transient ischemic attack.
a
Among the 5620 patients in the atrial fibrillation (AF) progression analysis, 260 were new mineralocorticoid antagonist (MRA) users and 5360 were not.
b
Among the 4174 patients in the new‐onset heart failure (HF) analysis, 121 were new MRA users and 4053 were not.